CAS 174722-31-7

Rituximab

Description:

Rituximab is a chimeric monoclonal antibody primarily used in the treatment of certain types of cancers, particularly non-Hodgkin lymphoma, and autoimmune diseases like rheumatoid arthritis. It specifically targets the CD20 antigen found on the surface of B cells, leading to the destruction of these cells through various mechanisms, including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Rituximab is administered via intravenous infusion and is known for its efficacy in depleting B cells, which can be beneficial in conditions characterized by excessive B cell activity. The drug's structure consists of both human and murine components, which contributes to its classification as a chimeric antibody. Common side effects may include infusion reactions, increased risk of infections, and potential cardiovascular complications. Rituximab has significantly impacted the treatment landscape for hematological malignancies and autoimmune disorders, demonstrating the importance of targeted therapies in modern medicine. Its development has paved the way for further research into monoclonal antibodies and their applications in various therapeutic areas.

Formula: Unspecified

Synonyms:

• Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 γ1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer
• Immunoglobulin G1
• Immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8 γ1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer
• IDEC 102
• Rituximab
• IDEC-C 2B8

USP mAb 001, Monoclonal IgG1

CAS: 174722-31-7

Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale

Color and Shape: Colorless Liquid

Ref: 45-1445539

Rituximab

CAS: 174722-31-7

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.Cost-effective and quality-assured.

Purity: 98% - 98.20%

Color and Shape: Liquid

Molecular weight: 148 kDa

Ref: TM-T9910

Rituximab - 20mg/ml solution

CAS: 174722-31-7

Rituximab is a glycosylated monoclonal antibody that binds to the CD20 cell surface protein which is widely expressed on B-cells. Through the binding of rituximab’s Fc portion, the antibody-dependent cellular cytotoxicity pathway (ADCC) and the complement-dependent cytotoxicity (CDC) pathway are initiated, both leading to B-cell lysis (Chisari, 2021). In addition, direct apoptosis can be the result of the inhibition of various B-cell signalling pathways. Rituximab is used in targeted therapy for chronic lymphocytic leukaemia (CLL), non-Hodgkin lymphoma (NHL) and some non-cancer pathologies, such as, multiple sclerosis (Johnson, 2001).

Formula: C₆₄₁₆H₉₈₇₄N₁₆₈₈O₁₉₈₇S₄₄

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 143769.11977

Ref: 3D-FR138503

Rituximab - 10mg/ml solution

CAS: 174722-31-7

Rituximab is a glycosylated monoclonal antibody that binds to the CD20 cell surface protein which is widely expressed on B-cells. Through the binding of rituximab’s Fc portion, the antibody-dependent cellular cytotoxicity pathway (ADCC) and the complement-dependent cytotoxicity (CDC) pathway are initiated, both leading to B-cell lysis (Chisari, 2021). In addition, direct apoptosis can be the result of the inhibition of various B-cell signalling pathways. Rituximab is used in targeted therapy for chronic lymphocytic leukaemia (CLL), non-Hodgkin lymphoma (NHL) and some non-cancer pathologies, such as, multiple sclerosis (Johnson, 2001).

Formula: C₆₄₁₆H₉₈₇₄N₁₆₈₈O₁₉₈₇S₄₄

Purity: Min. 95 Area-%

Color and Shape: Colorless Clear Liquid

Molecular weight: 143.86 kg/mol

Ref: 3D-BR167936